Mumbai: It started with unexplained complications and taking pictures pains in the neck, usually lasting minutes however typically for much longer. Inside weeks, she skilled dizziness, disorientation and a number of convulsions, forcing the household to hurry her to the native hospital. Inside six months, even strolling grew to become inconceivable. By then, a particularly frail Sita Devi (identify modified), 80, had left all the pieces to destiny. Her aggressive stage-4 lung cancer was quick metastasizing to her mind, making even visits to Dr Surendra Beniwal on the Acharya Tulsi Regional Cancer Institute and Analysis Centre in Bikaner extraordinarily tough. Her situation saved worsening: she doubled down with sharp pains and elevated heartbeat with each breath.Beneath the standard protocol, she would have had a biopsy take a look at adopted by radiation till palliative care remained the one approach out. However now she had one different choice: a brand new genomic take a look at known as next-generation sequencing (NGS), which quickly sorted by her DNA samples and picked out the exact genetic mutation that was more than likely making her sick.
NGS, the latest frontier in medical diagnostics, is quickly reworking affected person care. It decodes genomic knowledge and helps medical doctors translate that into personalised healthcare inside a number of days. It is a lifesaver particularly for cancer sufferers but in addition for folks with uncommon genetic issues and reproductive and inherited ailments. This is one of many largest leaps in a lab because the Eighties when the German bacteriologist Julius Petri got here up with a solution to isolate and analyse germ cultures in a gelatinous mattress of algae set between two nesting discs of glass.
NGS is step one in precision drugs versus the broadly practised one-size-fitsall therapies. Medical oncologist Dr Beniwal explains: “Devi had offered with an EGFR mutation [a mutation in the protein called epidermal growth factor receptor in lung cancer], which pinpointed to using a drug that focused precisely that.” So as a substitute of administering commonplace chemotherapy medication like carboplatin or paclitaxel, which might trigger painful side-effects, particularly at her age, he handled her with an osimertinib pill day by day. “Nearly a yr later, the previous girl, from a marginalised revenue stratum, walks on her personal and involves the centre for followups,” he says.Like with Devi, NGS is enabling therapy choices to be guided by mobile traits, usually main to raised outcomes, longer illness management and improved high quality of life. From tracing household ancestry to greedy particular person dietary profile, NGS appears to have nearly all of the solutions.
Dr Beniwal cites one other case of restoration. A 24-year-old lady had stage-two breast cancer. “Due to NGS and focused therapy, she might be saved from a number of problems of chemotherapy, costly antibiotics and neutropenia that results in low immunity,” he says. Immediately she leads a wholesome, regular life.
“The way forward for managing illness is not going to be a magic capsule,” says Hitesh Goswami, CEO of 4baseCare, a Bengaluru-based precision oncology and genomic testing startup, backed by Infosys and deeptech fund Yali Capital. “It is going to be about how we perceive and analyse a person’s knowledge, from DNA to demographics. The important thing might be to match the best affected person to the best therapy, each time, in all places.”
Scientists and researchers have already gene-mapped practically 4 million folks worldwide beneath NGS and generated effectively over a billion gigabytes of knowledge. The potential makes use of of that knowledge are multiplying yearly, says Suchita Dayanand, nation head, India (business), Illumina, a US-headquartered biotech firm that made genome sequencing accessible three a long time in the past.
Pharma firms too are on the hunt for the subsequent logical step: discovery of precision medication. Earlier this month, British pharma colossus GSK coughed up $10.6 billion for Nuvalent in US to get entry to a analysis pipeline of refined oncology medication.
“NGS is nothing in need of a revolution in the way forward for drugs,” says Ramakant Panda, heart specialist and founding father of Asian Coronary heart Institute, Mumbai.
WHAT HAPPENS
A DNA take a look at like NGS begins with a organic pattern equivalent to blood, saliva, tissue, or different related specimen, relying on the situation being examined for. The pattern is then processed on a sequencing machine that reads hundreds of thousands to billions of DNA constructing blocks, producing a digital map, and offers info on a person’s genes. The modifications in them, generally known as genetic alterations, can assist medical doctors perceive the reason for a illness, assess inherited dangers, predict how a affected person could reply to particular drugs and determine essentially the most acceptable therapy choices.
A genomic report is solely the start. Its actual affect is realised when it helps medical doctors choose the best remedy for a affected person. With out NGS, medical doctors are taking pictures in the darkish. They might prescribe medication that won’t work and even trigger extra hurt to sufferers.
Becoming a member of the medical gold rush of precision therapy are main hospital chains, younger startups, diagnostics networks and world buyers. By 2030, India’s genome sequencing market is anticipated to the touch $1.5 billion, a 27% CAGR in 4 years, with nationwide adoption. The precision drugs market is anticipated to develop fivefold to $5.8 billion, in line with trade estimates.
Apollo Hospitals runs genomics institutes in a dozen Indian cities and plans half a dozen extra. International suppliers of sequencing machines and panels for NGS like Illumina anticipate their India enterprise to develop three-five occasions over the subsequent seven years and are already supporting massive initiatives like Genome India and the Bharat Cancer Genome Atlas. Genome-testing labs like MedGenome, India’s largest pure-play genome diagnostics firm, and Relianceowned Strand Life Sciences have constructed proprietary NGS knowledge analytics platforms.
A fundamental take a look at beneath NGS for cancer can price Rs 20,000. It may possibly go up to Rs 4 lakh for a high-end panel with detailed, intensive screening.
ALLIANCE FOR ALL
To convey this expertise inside attain of people who find themselves in determined want of it, Cancer Analysis and Statistic Basis, a Mumbai-based nonprofit for cancer analysis and affected person care, has began an bold initiative known as the Lung Cancer Genomic Options (LuNGS) Alliance. It is a collaboration between oncologists, authorities hospitals, pharma firms like AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer and Roche, NBFCs like Tata Capital and the startup 4baseCare.
LuNGS Alliance makes TARGT First Strong, an NGS take a look at developed by 4baseCare that analyses generally mutated genes and prices at the least Rs 20,000, free for lung cancer sufferers. One affected person, categorised as distinctive, will get one take a look at without spending a dime.
Since March 2025, over 6,600 lung cancer sufferers in 700 cities and cities have gotten free NGS assessments by LuNGS Alliance and its community of oncologists in tier-2 and -3 cities and enormous metros. It is arguably the most important collaborative initiative in the nation to drive consciousness about precision oncology as a necessary, accessible and reasonably priced choice for lung cancer therapy.
Says Dr Kumar Prabhash, head of medical oncology division (stable tumour division) at Tata Memorial Hospital, Mumbai, and the driving pressure behind LuNGS Alliance: “Programmes like LuNGS Alliance have helped medical doctors in smaller cities make knowledgeable choices with out making it unaffordable for sufferers.”
“Oncology and neurology are the 2 fastest-growing illness segments globally. Naturally, these can have very excessive use circumstances for NGS,” says Ameera Shah, MD of the diagnostics chain Metropolis Healthcare, which acquired Core Diagnostics final yr to sharpen its concentrate on gene-sequencing expertise. She provides: “NGS is additionally used in the diagnosis of uncommon genetic issues in addition to being pregnant administration and neonatal care. Critically in poor health infants may be sequenced for early, life-saving interventions whereas a affected person’s complete genome may be scanned to search out that single mutation that is inflicting signs.”
MUTATIONS MATTER
With cancer rising as the most important illness section, NGS has change into the workhorse expertise underpinning multi-gene panel testing, analysing mutations in tons of and even hundreds of genes concurrently.
Cancer is brought on by random genetic modifications in wholesome cells over time. Mutations may be triggered by life-style decisions, familial predispositions, current well being circumstances and even publicity to hazardous chemical compounds. As they accumulate, mutated cells change into cancerous.
Each cancer is as distinctive as the person it afflicts, which implies even these recognized with the identical kind of cancer have solely a fraction of shared mutations. Every tumour is an intricate tapestry of billions of distinct cells, always studying to adapt and thwart therapeutic methods. In 2015, a cancer affected person would have undergone 4 separate assessments to determine 4 biomarkers, costing over Rs 20,000. For a similar value now, NGS assessments can throw up a minimal of fifty genetic mutations. In India, which has the third highest cancer circumstances and the place over 80% cancers are detected late, NGS may be an efficient intervention.
Strand Life Sciences, whereas not a part of LuNGS Alliance, offers assessments for a number of points—dietary necessities, drug tolerance and hereditary cancer dangers. “Past immunotherapy, genomics and next-generation sequencing are reworking practically each side of precision oncology—from figuring out actionable mutations (the place therapy is potential) and inherited cancer dangers to understanding tumour heterogeneity, therapy resistance and illness evolution on the single-cell stage,” says Ramesh Hariharan, CEO, Strand Life Sciences.
LOCAL IS LOGICAL
India has distinctive constraints: entry to population-specific genomic knowledge stays a white house. There aren’t any centralised, digital well being information. Mutation patterns in Indians differ from these in Caucasians. However world scientific trial knowledge for brand new medicines is not effectively represented by Indian sufferers. Southeast Asia, West Asia and the Indian subcontinent contribute to greater than half of the world’s cancer incidences—10 million new circumstances yearly—however there is scant knowledge particular to this cohort. For instance, KRAS gene mutation is seen in about 25% of non-small cell lung cancer sufferers in the West however solely in 10% of sufferers in India. EGFR mutation is seen in 10-15% of lung cancer sufferers in the West and 35% sufferers in India.
“Extra knowledge will assist us know the precise patterns in India,” says Dr Prabhash. “Inside India, there are severe contrasts. Circumstances in the Northeast might be very completely different from those in the South.”
That is the place the LuNGS Alliance turns into vital because it democratises precision drugs and saves lives.
Lung cancer accounts for practically 10% of cancer deaths in India. Based on International Cancer Observatory, 81,000 new circumstances are reported yearly and nearly two-thirds of sufferers succumb to this modern-day epidemic inside two years of diagnosis.
“This stark imbalance between incidence and mortality highlights the pressing want for data-driven precision approaches in therapy of lung cancer as a substitute of ordinary chemotherapy,” says Goswami of 4baseCare.
Of the 6,600 sufferers examined beneath LuNGS Alliance, studies of 58% confirmed actionable mutations that would instantly inform therapy choices. So 1 in 2 sufferers might doubtlessly profit from biomarker-directed remedy. Over 60% of samples got here from tier-2 and -3 cities. Rajasthan topped the chart with 858 samples, together with Sita Devi’s.
When LuNGS Alliance adopted up on 1,920 sufferers, it noticed real-world affect — 45% have been in a position to entry precision-based therapy.
“Cross-sector partnerships like LuNGS Alliance are enabling extra well timed, knowledgeable therapy choices in resource-constrained settings,” says Praveen Akkinepally, nation president, AstraZeneca India.
Meenakshi Nevatia, MD of Pfizer India, says it’s not nearly sequencing the gene: “It’s about understanding precisely what to make use of. The subsidy for the assessments is important.”
VOLUMES GAME
Nevertheless, subsidies alone can not galvanise a motion. Insurance coverage cowl for NGS and its integration with frequent assessments for diabetes or liver operate can unleash its full potential.
Entrepreneurs like Mohan Uttarwar, cofounder of 1Cell. AI, a cancer-testing startup, are mixing AI with cell biopsy for sharper outcomes to foretell tumour development. Says Uttarwar: “NGS is a disruptive innovation. Whereas assessments price $4,000-5,000 in US, it is a number of thousand rupees in India.” Vedam Ramprasad, CEO of MedGenome, says inclusion of NGS in authorities schemes equivalent to Ayushman Bharat will catalyse adoption on the grassroots stage and reverse the city skew. He provides: “Costs have already dropped and can fall additional. As soon as NGS turns into a part of frequent histopathology assessments (for tissue biopsy), it’s going to go mass.” In 2025, MedGenome purchased Inexperienced Cross Genetic Labs in Gujarat to develop its genomic diagnostics community.
However a genomic report like NGS is solely the beginning of the precision-medicine journey. Until it is backed by reasonably priced medicines, acceptance might be restricted in low- and middleincome nations. AstraZeneca’s Tagrisso (osimertinib) prices Rs 1.2-1.4 lakh for 10 tablets. A vial of the cancer drug Imfinzi is Rs 1.4 lakh whereas Bristol Myers Squibb’s immunotherapy drugs Opdyta prices Rs 1 lakh for a vial. Zydus Lifesciences has launched a generic model, Tishtha, for a fourth of that value.
The price of the medicines has to align with the altering economics of the assessments. “There are various limitations to implementing precision medicines. LuNGS Alliance offers entry to molecular assessments however efforts are additionally required to enhance entry to numerous medicines,” says Dr Prabhash.
Hospitals say test-based therapies are inevitable and may be made accessible by affected person help programmes. In the meantime, expiry of drug patents, launch of biosimilars and decrease price alternate options are altering trade dynamics. As extra sufferers acquire entry to precision medicines, the demand for genomic testing will rise quickly, making personalised cancer therapy a routine a part of care, moderately than an choice for a selected few. In any case, time is of the essence for all cancer sufferers.
Source link
#Scanning #cancer #close #private #revolution #underway #cancer #diagnosis
